Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results
| Autor: | Viera Sandecká, Marta Krejčí, Darina Očadlíková, Lenka Zahradová, Klára Mollová, L. Kovarova, Krivanová A, Zdeněk Adam, Roman Hájek, Luděk Pour |
|---|---|
| Přispěvatelé: | L. ZAHRADOVA, K. MOLLOVA, D. OCADLIKOVA, L. KOVAROVA, Z. ADAM, M. KREJCI, L. POUR, A. KRIVANOVA, V. SANDECKA, R. HAJEK |
| Rok vydání: | 2012 |
| Předmět: |
Male
Cancer Research dendritic cell medicine.medical_treatment Phases of clinical research Enzyme-Linked Immunosorbent Assay Cancer Vaccines 03 medical and health sciences 0302 clinical medicine Immune system Adjuvants Immunologic medicine Humans Cumulative incidence Hypersensitivity Delayed Survival rate Multiple myeloma 030304 developmental biology Aged Neoplasm Staging 0303 health sciences business.industry ELISPOT anticancer vaccine Vaccination Immunotherapy Dendritic Cells Id-protein Middle Aged medicine.disease Prognosis 3. Good health Survival Rate Oncology 030220 oncology & carcinogenesis Case-Control Studies Immunology Hemocyanins Female Inhibitor of Differentiation Proteins business Multiple Myeloma |
| Zdroj: | Neoplasma. 59(4) |
| ISSN: | 0028-2685 |
| Popis: | In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p= 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.dendritic cells, immunotherapy, anticancer vaccines, Id-protein, multiple myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|